127 related articles for article (PubMed ID: 21867645)
21. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
[TBL] [Abstract][Full Text] [Related]
22. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
23. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
24. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
25. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
26. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
27. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Tsimberidou AM; Colburn DE; Welch MA; Cortes JE; Verstovsek S; O'Brien SM; Albitar M; Kantarjian HM; Giles FJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):229-34. PubMed ID: 12783207
[TBL] [Abstract][Full Text] [Related]
28. [Abnormal activation of tyrosine kinases and its role in the pathogenesis of hematological malignancies - review].
Sun XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):657-61. PubMed ID: 17605888
[TBL] [Abstract][Full Text] [Related]
29. [Imatinib in treatment of thrombocythemia and other myeloproliferative diseases].
Shu LL; Yang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1507-12. PubMed ID: 23257463
[TBL] [Abstract][Full Text] [Related]
30. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.
Mughal TI; Barbui T; Abdel-Wahab O; Kralovics R; Jamieson C; Kvasnicka HM; Mullaly A; Rampal R; Mesa R; Kiladjian JJ; Deininger M; Prchal J; Hehlmann R; Saglio G; Van Etten RA
Leuk Lymphoma; 2015 Jul; 56(7):1938-48. PubMed ID: 25330439
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for myeloproliferative neoplasms (MPN).
Hofmann S; Babiak A; Greiner J
Curr Cancer Drug Targets; 2011 Jan; 11(1):72-84. PubMed ID: 21062247
[TBL] [Abstract][Full Text] [Related]
32. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
33. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders.
Reiter A; Walz C; Cross NC
Curr Drug Targets; 2007 Feb; 8(2):205-16. PubMed ID: 17305499
[TBL] [Abstract][Full Text] [Related]
34. Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy.
Tang TC; Chang H; Chuang WY
Acta Haematol; 2012; 128(2):83-7. PubMed ID: 22722648
[TBL] [Abstract][Full Text] [Related]
35. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
36. New insights into small-molecule inhibitors of Bcr-Abl.
Schenone S; Bruno O; Radi M; Botta M
Med Res Rev; 2011 Jan; 31(1):1-41. PubMed ID: 19714578
[TBL] [Abstract][Full Text] [Related]
37. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.
Macdonald D; Cross NC
Pathobiology; 2007; 74(2):81-8. PubMed ID: 17587879
[TBL] [Abstract][Full Text] [Related]
38. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
39. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
40. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
